Table 3.

Analysis of influencing factors associated with posterior capsular opacification in highly myopic eyes

Variables	Eyes (n)	Clinically significant PCO	P-value
Age (years)
< 60	192	46.4% (89/192)
60–70	339	44.0% (149/339)
> 70	142	29.6% (42/142)	0.004
Gender
Male	262	40.5% (106/262)
Female	411	42.3% (174/411)	0.688
Follow-up duration (years)
1–2	128	15.6% (20/128)
2–3	244	36.1% (88/244)
> 3	301	57.1% (172/301)	< 0.001
Diabetes
With	57	38.6% (22/57)
Without	616	41.9% (258/616)	0.827
IOL type
Humanoptics	346	40.5% (140/346)
Rayner	327	42.8% (140/327)	0.584
IOL power (D)
< 10D	376	48.7% (183/376)
≥ 10D	297	32.7% (97/297)	< 0.001
IOL thickness (mm)
< 0.74 mm	342	43.6% (149/342)
≥ 0.74 mm	331	39.6% (131/331)	0.294

EPCO Evaluation of posterior capsular opacification, PCO-3 mm EPCO score within the central 3.0 mm zone, PCO-C EPCO score within the capsulorhexis margin, Nd:YAG neodymium-doped yttrium aluminum garnet, IOL intraocular lens

Data were presented as mean ± standard deviation or percentage (proportion)

Difference of clinically significant PCO rate among different groups was analyzed by χ² test